Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
Identifieur interne : 000075 ( Main/Exploration ); précédent : 000074; suivant : 000076Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
Auteurs : Eugenia Mamikonyan [États-Unis] ; Sharon X. Xie [États-Unis] ; Emilie Melvin [États-Unis] ; Daniel Weintraub [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal patch. The primary outcome measure was the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). Secondary outcomes included the Montreal Cognitive Assessment (MoCA), Dementia Rating Scale-2 (DRS-2), Neurotrax computerized cognitive battery, the Everyday Cognition Battery (ECB), and the Parkinson's Disease Questionnaire (PDQ-8). Twenty-six participants (92.9%) completed both study phase assessments, and 23 (82.1%) completed both phases on study medication. The CGIC response rate demonstrated a trend effect in favor of rivastigmine (regression coefficient for interaction term in linear mixed-effects model = 0.44, F[df] = 3.01 [1, 24], P = 0.096). For secondary outcomes, a significant rivastigmine effect on the ECB (regression coefficient = -2.41, F[df] = 5.81 [1, 22.05], P = 0.03) was seen, but no treatment effect was found on any cognitive measures. Trend effects also occurred in favor of rivastigmine on the PDQ-8 (regression coefficient = 4.55, F[df] = 3.93 [1, 14. 79], P = 0.09) and the State Anxiety Inventory (regression coefficient = -1.24, F[df] = 3.17 [1, 33], P = 0.08). Rivastigmine in PD-MCI showed a trend effect for improvements on a global rating of cognition, disease-related health status, and anxiety severity, and significant improvement on a performance-based measure of cognitive abilities. © 2015 International Parkinson and Movement Disorder Society.
DOI: 10.1002/mds.26236
PubMed: 25914281
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000179
- to stream PubMed, to step Curation: 000179
- to stream PubMed, to step Checkpoint: 000075
- to stream Ncbi, to step Merge: 004339
- to stream Ncbi, to step Curation: 004339
- to stream Ncbi, to step Checkpoint: 004339
- to stream Main, to step Merge: 000075
- to stream Main, to step Curation: 000075
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.</title><author><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Xie, Sharon X" sort="Xie, Sharon X" uniqKey="Xie S" first="Sharon X" last="Xie">Sharon X. Xie</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Melvin, Emilie" sort="Melvin, Emilie" uniqKey="Melvin E" first="Emilie" last="Melvin">Emilie Melvin</name><affiliation wicri:level="2"><nlm:affiliation>Duke University, Durham, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke University, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="3"><nlm:affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25914281</idno><idno type="pmid">25914281</idno><idno type="doi">10.1002/mds.26236</idno><idno type="wicri:Area/PubMed/Corpus">000179</idno><idno type="wicri:Area/PubMed/Curation">000179</idno><idno type="wicri:Area/PubMed/Checkpoint">000075</idno><idno type="wicri:Area/Ncbi/Merge">004339</idno><idno type="wicri:Area/Ncbi/Curation">004339</idno><idno type="wicri:Area/Ncbi/Checkpoint">004339</idno><idno type="wicri:Area/Main/Merge">000075</idno><idno type="wicri:Area/Main/Curation">000075</idno><idno type="wicri:Area/Main/Exploration">000075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.</title><author><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Xie, Sharon X" sort="Xie, Sharon X" uniqKey="Xie S" first="Sharon X" last="Xie">Sharon X. Xie</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Melvin, Emilie" sort="Melvin, Emilie" uniqKey="Melvin E" first="Emilie" last="Melvin">Emilie Melvin</name><affiliation wicri:level="2"><nlm:affiliation>Duke University, Durham, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke University, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="3"><nlm:affiliation>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</wicri:regionArea><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal patch. The primary outcome measure was the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). Secondary outcomes included the Montreal Cognitive Assessment (MoCA), Dementia Rating Scale-2 (DRS-2), Neurotrax computerized cognitive battery, the Everyday Cognition Battery (ECB), and the Parkinson's Disease Questionnaire (PDQ-8). Twenty-six participants (92.9%) completed both study phase assessments, and 23 (82.1%) completed both phases on study medication. The CGIC response rate demonstrated a trend effect in favor of rivastigmine (regression coefficient for interaction term in linear mixed-effects model = 0.44, F[df] = 3.01 [1, 24], P = 0.096). For secondary outcomes, a significant rivastigmine effect on the ECB (regression coefficient = -2.41, F[df] = 5.81 [1, 22.05], P = 0.03) was seen, but no treatment effect was found on any cognitive measures. Trend effects also occurred in favor of rivastigmine on the PDQ-8 (regression coefficient = 4.55, F[df] = 3.93 [1, 14. 79], P = 0.09) and the State Anxiety Inventory (regression coefficient = -1.24, F[df] = 3.17 [1, 33], P = 0.08). Rivastigmine in PD-MCI showed a trend effect for improvements on a global rating of cognition, disease-related health status, and anxiety severity, and significant improvement on a performance-based measure of cognitive abilities. © 2015 International Parkinson and Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Pennsylvanie</li></region><settlement><li>Philadelphie</li></settlement></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Mamikonyan, Eugenia" sort="Mamikonyan, Eugenia" uniqKey="Mamikonyan E" first="Eugenia" last="Mamikonyan">Eugenia Mamikonyan</name></region><name sortKey="Melvin, Emilie" sort="Melvin, Emilie" uniqKey="Melvin E" first="Emilie" last="Melvin">Emilie Melvin</name><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><name sortKey="Xie, Sharon X" sort="Xie, Sharon X" uniqKey="Xie S" first="Sharon X" last="Xie">Sharon X. Xie</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000075 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000075 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25914281
|texte= Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25914281" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |